News & Events

• January 19, 2021
  

  C-Path’s PKDOC Presentation on Fluid-Based Biomarkers

  Critical Path Institute’s John-Michael Sauer, Ph.D. presents information on fluid-based biomarkers and how they can be applied to help advance polycystic kidney disease drug development for patients across the globe. C-Path’s Polycystic Kidney Disease Outcomes Consortium investigates tools and promotes research that will lead to the development and regulatory approval of new therapies for PKD. Watch now: https://youtu.be/4OXEMYXpOvI...
• October 9, 2020
  

  Webinar: Accelerating Drug Development for Rare Diseases through Data Sharing and Analysis (Sept.18, 2020)

  Despite increasing numbers of drug targets and technologies, rare disease drug development is frequently slowed by the low numbers of patients and the lack of comprehensive quantitative characterization of diseases. Tucson’s Critical Path Institute (C-Path), along with the National Organization of Rare Disorders (NORD) and the FDA, have developed an integrated database and analytics hub called the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) to help accelerate clinical development, make it less expensive, and encourage new companies to develop treatments for rare diseases.

  Presenters: Jane Larkindale, DPhil, Critical Path Institute, Executive Director Rare Disease Cures Accelerator-Data and Analytics Platform; Duchenne Regulatory Science Consortium

  Vanessa Boulanger, MSc, National Organization for Rare Disorders, Director of Research Programs

  Michelle Campbell, PhD, U.S. Food and Drug Administration, Sr. Clinical Analyst for Stakeholder Engagement and Clinical Outcomes, Division of Neurology Products

• October 9, 2020
  

  How Math, Statistics, and Artificial Intelligence Can be Used to Develop Treatments for Major Diseases: Quantitative Medicine at the Critical Path Institute

  This presentation focuses on the bridge between a person’s ultimate health in light of being affected by a debilitating disease, and how a novel treatment for that disease can be back-tracked to the use of quantitative methods to help guide the development of such novel treatments. Case studies in multiple diseases including, Alzheimer’s, Parkinson’s, type-1 diabetes and polycystic kidney disease will be shown to demonstrate the process.

  Presenter: Jackson Burton, PhD, Executive Director, C-Path Quantitative Medicine Program

• October 9, 2020
  

  New Uses for Existing Drugs: Applications for COVID-19 and Valley Fever

  What is drug repurposing and why is it important? Learn more about the CURE ID web-based app made possible by the National Center for Advancing Translational Sciences (NCATS) and its utility for COVID-19 and Valley Fever. Health care professionals are encouraged to attend.

  Presenter: Marco Schito, PhD, C-Path Executive Director, Cure Drug Repurposing Collaboratory

• October 9, 2020
  

  Drug Development and Regulation in the Age of Precision Medicine

  An introduction and overview of the Critical Path Institute and University of Arizona collaboration and the regulatory science graduate program and courses. Plus, a deep dive into precision medicine as a disruptive force across all aspects of the health care system. Specifically, how the development of precision medicine based-therapies continue to pose challenges related to scientific discovery, diagnostic regulatory policy, investment incentives, coverage and reimbursement, and the implementation of new technologies into clinical practice.

  Presenters: John-Michael Sauer, PhD, C-Path Biomarker Program Officer and Executive Director of the Predictive Safety Testing Consortium

  Tara Sklar, JD, MPH, Professor of Health Law, Director, Health Law & Policy Program